CIMBALA@BIONET-20.ARPA (03/10/88)
From: Michele A. Cimbala <CIMBALA@BIONET-20.ARPA>
Return-Path: <@CUNYVM.CUNY.EDU:CZJ@NIHCU.BITNET>
Received: from CUNYVM.CUNY.EDU by BIONET-20.ARPA with TCP; Mon 7 Mar 88 04:09:15-PST
Received: from NIHCU.BITNET by CUNYVM.CUNY.EDU ; Mon, 07 Mar 88 07:10:37 EST
To: science-resources@bionet-20.arpa
From: CZJ%NIHCU.BITNET@CUNYVM.CUNY.EDU
Date: Mon, 07 Mar 88 07:09:36 EST
Attached is the NIH guide to Grants and Contracts 2/26/88. Included
is the Index and items of interest.
Jim Cassatt
-------------------------------------------------------------------
Vol. 17, No. 7, February 26, 1988
NOTICES
Presolicitation for: RESEARCH FOR ALCOHOL-RELATED BEHAVIOR THAT
INCREASES THE RISK OF AIDS AND/OR RESEARCH ON PREVENTION
STRATEGIES TO REDUCE THAT RISK..........(84/131)............................ 1
National Institute on Alcohol Abuse and Alcoholism
Index: ALCOHOL ABUSE AND ALCOHOLISM
INDIVIDUAL POSTDOCTORAL FELLOWSHIP (F32) APPLICATIONS
LETTERS OF REFERENCE...................(134/187)............................ 1
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
TWO NEW PUBLICATIONS AVAILABLE FROM THE NATIONAL EYE INSTITUTE.............. 2
National Eye Institute (190/233)
Index: EYE
THE MIT CELL CULTURE CENTER.............(241/286)........................... 3
Division of Research Resources
Index: RESEARCH RESOURCES
GUIDELINES FOR FEDERAL STATISTICAL ACTIVITIES.....(289/322)................. 3
Office of Management and Budget
Index: OFFICE OF MANAGEMENT AND BUDGET
DATED ANNOUNCEMENTS (RFPs AND RFAs)
CLINICAL COORDINATING CENTER FOR A REGISTRY OF PATIENTS WITH
SEVERE CONGENITAL DEFICIENCY OF ALPHA1-ANTITRYPSIN (RFP)....(328/409)....... 4
National Heart, Lung, and Blood Institute
Index: HEART, LUNG AND BLOOD INSTITUTE
VARIABLE FIELD T1 AND T2 ANALYZER: DESIGN AND CONSTRUCTION (RFP)........... 5
National Institute of Neurological and Communicative Disorders and Stroke
Index: NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE (412/446)
POSITRON EMISSION TOMOGRAPH (PET) SCANNER (RFP)......(449/470).............. 5
Clinical Center
Index: CLINICAL CENTER
LITERATURE SURVEILLANCE AND SELECTION OF PROMISING NATURAL PRODUCTS (RFP)... 6
National Cancer Institute (481/542)
Index: CANCER
CONSEQUENCES OF EARLY CHILDBEARING IN THE 1980's (RFP)....(545/594)......... 6
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT
CENTERS FOR AIDS RESEARCH (RFA)..............(597/700, 1204/1988)........... 7
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES
EFFECTS OF NON-PARENTAL INFANT DAY CARE ON CHILD DEVELOPMENT
REQUEST FOR COOPERATIVE AGREEMENT APPLICATION (RFA)....(703/849)............ 8
National Institute of Child Health and Human Development (1991/2661)
Index: CHILD HEALTH AND HUMAN DEVELOPMENT
PREVENTIVE PULMONARY ACADEMIC AWARD....................(1852/944)...........10
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD INSTITUTE
RESEARCH ON INFECTIOUS AGENTS IN THE ETIOLOGY
OF RHEUMATOID ARTHRITIS................................(947/1083)...........11
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Index: ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
MENTAL HEALTH CLINICAL TRAINING GRANTS: INDIVIDUAL
FACULTY SCHOLAR AWARDS................................(1086/1154)...........13
National Institute of Mental Health
Index: MENTAL HEALTH
--------------------------------------------------------------------
INDIVIDUAL POSTDOCTORAL FELLOWSHIP (F32) APPLICATIONS
LETTERS OF REFERENCE
P.T. 22; K.W. 0720005, 1014002
National Institutes of Health
The NIH is working to reduce the time required for completion of the receipt,
referral, review, and award of individual postdoctoral fellowship (F32)
applications. The goal is to cut the current time of eight to nine months in
half. Accomplishing this goal would benefit candidates and their sponsors by
giving them more time for planning future research training activities.
To help expedite the review process, NIH is now requiring that at least three
completed, sealed letters of reference be submitted with each individual
fellowship application.
Four copies of the reference forms are included in each fellowship application
kit. Candidates should:
1. Send these forms to their referees well in advance of the application
submission date, and advise the referees to complete the form and return it to
the candidate in a sealed envelope as soon as possible;
1
2. Request reference reports only from individuals who will be able to return
them in time for the application submission. Consider any factor (e.g.,
illness or overseas sabbatical, etc.) that might cause an inordinate delay;
3. Choose individuals, other than the sponsor of the application, who can
make the most meaningful comments about the candidate's qualifications for a
research career;
4. If applicable, include a reference from the current mentor or immediate
supervisor. If not submitting a reference from the thesis advisor or chief of
service, explain why in Item 23 of the application;
5. Where possible, select at least one respondent who is not in the
candidate's current department; and
6. Select graduate or medical school referees rather than those from
undergraduate schools.
To protect the utility and confidentiality of reference letters, candidates
are asked not to open the envelopes. The sealed envelopes should be attached
to the original application.
Applications with fewer than three references will be returned. Candidates
reapplying (competing continuations or revised applicants) must submit new
reference forms to facilitate the expedited review process.
These procedures are effective as of the May 10, 1988, receipt deadlines.
TWO NEW PUBLICATIONS AVAILABLE FROM THE NATIONAL EYE INSTITUTE
P.T. 34; K.W. 1014017, 1002046
National Eye Institute
"1987 UPDATE AND EVALUATION, VISION RESEARCH--A NATIONAL PLAN 1983-1987"
The National Advisory Eye Council's most recent evaluation of the research
needs and opportunities in vision research is now available from the NEI. The
354-page "1987 Evaluation and Update" provides assessments by panels of expert
consultants of the research needs and opportunities in each of the NEI's major
research program areas: Retinal and Choroidal Diseases; Corneal Diseases;
Cataract; Glaucoma; and Strabismus, Ambylopia, and Visual Processing. The
Update discusses the current status of research, highlights major
accomplishments, and outlines the NEI's research priorities. To obtain a copy
of the the "1987 Evaluation and Update", please write to:
Mr. Julian Morris
Associate Director for Planning and Reporting
National Eye Institute
National Institutes of Health
Building 31, Room 6A27
Bethesda, Maryland 20892
"CLINICAL TRIALS SUPPORTED BY THE NATIONAL EYE INSTITUTE: EVALUATING NEW
APPROACHES TO THE TREATMENT OF EYE AND VISION DISORDERS"
The NEI has published a 67-page booklet, "Clinical Trials Supported by the
National Eye Institute: Evaluating New Approaches to the Treatment of Eye and
Vision Disorders." The booklet describes 17 randomized controlled clinical
trials currently supported by the NEI. This publication gives information on
each trial's purpose and design, patient recruitment goal and eligibility
criteria, current status, and bibliography. The names of study chairmen,
professional and institutional participants, and data and safety monitoring
committee members are provided, as well as locations of clinical centers and
resource centers. To obtain a copy of the booklet, please write to:
Ms. Judith Stein
Information Officer
National Eye Institute
National Institutes of Health
Building 31, Room 6A32
Bethesda, Maryland 20892
2
THE MIT CELL CULTURE CENTER
P.T. 36; K.W. 0780005, 0780015
Division of Research Resources
The MIT Cell Culture Center is a national resource available for researchers
to obtain large quantities of animal cells, cell products, and viruses. The
primary goal of this large-scale production center is to allow scientists to
conduct research that they can not accomplish with the facilities available in
their own laboratories. The Center, headed by Dr. Phillip A. Sharp, provides
cells in suspension and monolayer cultures, typically in amounts ranging from
10 to 200 liters of suspension culture cells and 50 to 200 roller bottles of
cells. Previous projects have included: 100 roller bottles of Balb 3T3
cells, 200 liters of HeLa S-3 cells, and 800 liters of a human lymphoblastoid
cell line. An application form, obtained from the Center, must contain a
description of the relevant research project. Following the approval of the
application by the Operating Committee of the Center, the investigator sends a
stock of the cells or virus to the Center, and the stock is then grown to the
requested amount. Researchers are charged only for the consumable material
used on the project plus a small portion of the labor costs. Application
forms and inquiries should be directed to:
Donald J. Giard
Director, MIT Cell Culture Center
E17-321
Massachusetts Institute of Technology
Cambridge, Massachusetts 02139
Telephone: (617) 253-6430
The Center also contains a Cell Sorter Laboratory for flow cytometry and
sorting. Available instrumentation includes the System 6OH by Ortho
Diagnostics Systems interfaced with the model 2150 computer unit for data
aquisition, storage, and analysis. The Center welcomes inquiries about
special needs for researchers' projects. Users are required to pay a fee to
cover part of the operational costs. Inquiries about the cell sorter services
should be directed to:
Mr. Paul Kaye
E17-358
Massachusetts Institute of Technology
Cambridge, Massachusetts 02139
Telephone: (617) 253-6454
The MIT Cell Culture Center is supported by the Division of Research
Resources, NIH.
------------------------------------------------------------------
LITERATURE SURVEILLANCE AND SELECTION OF PROMISING NATURAL
PRODUCTS
RFP AVAILABLE: NCI-CM-97562-27
P.T. 34; K.W. 1103002, 1004017, 0750025, 1003012
National Cancer Institute
The Natural Products Branch (NPB), Developmental Therapeutics Program (DTP),
Division of Cancer Treatment (DCT), National Cancer Institute (NCI), is
seeking organizations having capabilities, resources and facilities to: (1)
perform literature searches of pertinent current journals and abstracting
services in and related to the natural product area; (2) identify and review
articles and abstracts relating to antineoplastic agents in 150-200 different
journals; (3) select information on new natural product compounds which may be
active against cancer; and (4) select previously reported natural products and
their analogs showing newly reported biological activities related to
anticancer activity.
Sources of the natural products will be plants and animals, including
microbial, fungal, and marine sources. Reports will provide data on (a)
chemical composition and (b) biological activity of extracts of purified
compounds obtained from natural products.
The definition of natural products chemistry, generally accepted by the
scientific community, is the chemistry of the isolation, identification, and
metabolic pathways of compounds originating from plants, animals (both
vertebrates and invertebrates, including insects), marine organisms, bacteria,
algae, and fungi. Although in the broadest sense it may include humans,
rodents and other animals and their products used in cancer research, for this
project the study of natural products includes only those organisms mentioned
above and their products. Therefore, research experience with humans,
rodents, or other experimental animals, or their products, will not reflect
experience of the sort required for this project. It is preferred that the
principal investigator (PI) shall have a Ph.D. degree in organic, medicinal or
natural products chemistry, or a closely related discipline, and should have
training in and recent experience with natural products structures (at least 5
years) and chemical searches (at least 2 years) as well as experience with
evaluation and interpretation of biological data, preferably in the cancer
area (at least 5 years). The P.I. should have in-depth knowledge of the
natural products area and ready familiarity with organic and medicinal
chemistry for the selection of articles and chemical structures of probable
interest to NCI.
It is anticipated that an incrementally funded contract will be awarded for a
period of three years beginning on or about October 26, 1988.
RFP No. NCI-CM-97562-27 will be issued on or about February 26, 1988, and
proposals will be due approximately six (6) weeks thereafter. The proposed
procurement is under a 100 percent small business set-aside, the size standard
for which is 500 employees.
The RFP Package will be available upon written request to:
Johnny Jordan
Contract Specialist
Treatment Contracts Section, RCB
National Cancer Institute, NIH
Blair Building, Room 216
Bethesda, Maryland 20892
Telephone: (301) 427-8737
-------